References
- Wong BS, Camilleri M, Carlson PJ, Guicciardi ME, Burton D, McKinzie S, A Klothoβ variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea. Gastroenterology 2011;140:1934–42.
- Kurien M, Evans KE, Leeds JS, Hopper AD, Harris A, Sanders DS. Bile acid malabsorption: An under-investigated differential diagnosis in patients presenting with diarrhea predominant irritable bowel syndrome type symptoms. Scand J Gastroenterol 2011;46:818–22.
- Van Hoboken EA, Thijssen AY, Verhaaren R, van der Veek PPJ, Prins FA, Verspaget HW, Masclee AM. Symptoms in patients with ulcerative colitis in remission are associated with visceral hypersensitivity and mast cell activity. Scand J Gastroenterol 2011;46:981–7.
- Schmidt M, Hausken T, Glambek I, Schleer C, Eide GE, Søndenaa K. A 24-year controlled follow-up of patients with silent gallstones showed no long-term risk of symptoms or adverse events leading to cholecystectomy. Scand J Gastroenterol 2011;46:949–54.
- Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS, Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology 2011;53:336–45.
- Welker M-W, Hofmann WP, Lange CM, Herrmann E, Sarazin C, Zeuzem C, Kronenberger B. CD81 expression for discrimination between sustained virologic response and relapse in patients with chronic hepatitis C. Scand J Gastroenterol 2011;46:973–80.
- Nakamoto S, Kanda T, Imazeki F, Wu S, Arai M, Fujiwara K, Yokosuka O. Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients. Scand J Gastroenterol 2011;46:955–61.
- Stibbe KJM, Verveer C, Francke J, Hansen BE, Zondervan PE, Kuipers E, Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients. Scand J Gastroenterol 2011;46:962–72.
- Raju N, Sobieraj-Teague M, Hirsh J, O'Donnell M, Eikelboom J. Effect of Aspirin on Mortality in the Prevention of Cardiovascular Disease. Am J Med 2011; [Epub ahead of print].
- Sostres C. Lanas A Gastrointestinal effects of aspirin. Nat Rev Gastroenterol Hepatol 2011; [Epub ahead of print].
- Saini SD, Fendrick AM, Scheiman JM. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention. Aliment Pharmacol Ther 2011;34:243–51.
- Banoob DW, McCloskey WW, Webster W. Risk of gastric injury with enteric- versus nonenteric-coated aspirin. Ann Pharmacother 2002;36:163–6.
- Hirata Y, Kataoka H, Shimura T, Mizushima T, Mizoshita T, Tanida S, Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin. Scand J Gastroenterol 2011;46:803–9.
- Shibuya T, Ohkusa T, Yokoyama T, Matsumoto K, Beppu K, Sakamoto N, Colonic mucosal lesions associated with low-dose aspirin: A case control study. Scand J Gastroenterol 2011;46:810–17.